Neurohealing receives FDA orphan drug designation for NH001 for the treatment of patients in a vegetative state or minimally conscious state following brain injury

Newton, Mass., May 25, 2006 NeuroHealing Pharmaceuticals, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug status to NH001 for the treatment of patients in a vegetative state or minimally conscious state for up to twelve months following a brain injury (traumatic…

Life Science Angels Invests in NeuroHealing Pharmaceuticals. Company is Preparing for Two Phase II Clinical Trials: one to Aid Patients Recovering from Coma and another to Treat Sialorrhea in Parkinson’s Disease

Palo Alto, Calif. and Newton, Mass., April 05, 2006 — PRNewswire Life Science Angels, Inc., a Bay Area healthcare angel investment group focused exclusively on early stage biotechnology and medical device companies, announced today an investment in NeuroHealing Pharmaceuticals, Inc. NeuroHealing Pharmaceuticals is a clinical stage company developing therapies to improve the neuro-rehabilitation process and…

NeuroHealing Announces Presentation of Preliminary Results of Clinical Studies of NH001 for Coma Patients at 4th World NeuroRehabilitation Congress, feb 12-16, 2006

Newton, Mass., February 10, 2006. NeuroHealing Pharmaceuticals Inc., a private company developing products for individuals with chronic brain injuries, announces that preliminary results from its ongoing clinical studies of NH001 for coma patients will be presented by Dr. Esteban Fridman at the 4th World Neurorehabilitation Congress to take place in Hong Kong on February 12-16,…

NeuroHealing Pharmaceuticals Announces IND Clearance for NH001 to Improve The Outcome of Patients in a Vegetative State Following a Traumatic Brain Injury

Newton, Mass., January 17, 2006 NeuroHealing Pharmaceuticals Inc., a private company developing products for individuals with chronic brain injuries, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a 76-patients, Phase II clinical trial with NH001. The study is entitled “A Double-Blind, Placebo-Controlled, Randomized…

NeuroHealing Pharmaceuticals to Present at Rodman & Renshaw Techvest Seventh Annual HealthCare Conference

NEWTON, MA, November 3, 2005. NeuroHealing Pharmaceuticals, Inc., a private company developing therapeutic products for individuals with chronic brain injuries, today announced that Neal M. Farber, Ph.D., CEO of NeuroHealing, is scheduled to present at the upcoming Rodman & Renshaw Techvest Seventh Annual Healthcare Conference. Dr. Farber will present information on NeuroHealing’s three clinical stage…

NeuroHealing Pharmaceuticals announces IND submission for NH001 to improve the outcome of patients in a vegetative state following a traumatic brain injury

Newton, Mass., August 31, 2005 — E-Worldwire NeuroHealing Pharmaceuticals Inc., a private company developing products for individuals with chronic brain injuries, announced today the submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial with NH001. The study is entitled “A Double-Blind,…